Journal of Jilin University(Medicine Edition) ›› 2021, Vol. 47 ›› Issue (5): 1323-1330.doi: 10.13481/j.1671-587X.20210534
• Review • Previous Articles Next Articles
Received:
2020-11-02
Online:
2021-09-28
Published:
2021-10-26
CLC Number:
1 | CORLESS C L, HEINRICH M C. Molecular pathobiology of gastrointestinal stromal sarcomas[J]. Annu Rev Pathol, 2008, 3: 557-586. |
2 | SCHMIEDER M, HENNE-BRUNS D, MAYER B, et al. Comparison of different risk classification systems in 558 patients with gastrointestinal stromal tumors after R0-resection[J]. Front Pharmacol, 2016, 7: 504. |
3 | CAMERON S. Long-term adjuvant treatment of gastrointestinal stromal tumors (GIST) with imatinib-a comment and reflection on the PERSIST-5 study[J]. Transl Gastroenterol Hepatol, 2018, 3: 16. |
4 | CHEN T, XU L, YE L, et al. A new nomogram for recurrence-free survival prediction of gastrointestinal stromal tumors: Comparison with current risk classification methods[J].Eur J Surg Oncol,2019,45(6):1109-1114. |
5 | LIU X, CHU K M. Molecular biomarkers for prognosis of gastrointestinal stromal tumor[J]. Clin Transl Oncol, 2019, 21(2): 145-151. |
6 | GAO Z, WANG C, XUE Q, et al. The cut-off value of tumor size and appropriate timing of follow-up for management of minimal EUS-suspected gastric gastrointestinal stromal tumors[J]. BMC Gastroenterol, 2017, 17(1): 8. |
7 | HU M L, WU K L, CHANGCHIEN C S, et al. Endosonographic surveillance of 1-3 cm gastric submucosal tumors originating from muscularis propria[J].World J Gastroenterol,2017,23(12):2194-2200. |
8 | WANG M, XUE A, YUAN W, et al. Clinicopathological features and prognosis of small gastric gastrointestinal stromal tumors (GISTs)[J]. J Gastrointest Surg, 2019, 23(11): 2136-2143. |
9 | ZHENG J, LI R, QIU H, et al. Tumor necrosis and >20 mitoses per 50 high-power fields can distinguish ‘very high-risk’ and ‘highest-risk’ within ‘high-risk’ gastric gastrointestinal stromal tumor[J]. Future Oncol, 2018, 14(7): 621-629. |
10 | MIETTINEN M, LASOTA J. Gastrointestinal stromal tumors: pathology and prognosis at different sites[J]. Semin Diagn Pathol, 2006, 23(2): 70-83. |
11 | CORLESS C L, BALLMAN K V, ANTONESCU C R,et al. Pathologic and molecular features correlate with long-term outcome after adjuvant therapy of resected primary GI stromal tumor: the ACOSOG Z9001 trial[J]. J Clin Oncol, 2014, 32(15): 1563-1570. |
12 | JOENSUU H. Risk stratification of patients diagnosed with gastrointestinal stromal tumor[J]. Hum Pathol, 2008, 39(10): 1411-1419. |
13 | CASALI P G, ABECASSIS N, ARO H T, et al. Gastrointestinal stromal tumours: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up[J]. Ann Oncol, 2018, 29():iv68-iv78. |
14 | NISHIDA T, HØLMEBAKK T, RAUT C P, et al. Defining tumor rupture in gastrointestinal stromal tumor[J]. Ann Surg Oncol, 2019, 26(6): 1669-1675. |
15 | HØLMEBAKK T, HOMPLAND I, BJERKEHAGEN B,et al. Recurrence-free survival after resection of gastric gastrointestinal stromal tumors classified according to a strict definition of tumor rupture: a population-based study[J]. Ann Surg Oncol, 2018, 25(5): 1133-1139. |
16 | YANG D Y, WANG X, YUAN W J, et al. Metastatic pattern and prognosis of gastrointestinal stromal tumor (GIST):a SEER-based analysis[J]. Clin Transl Oncol, 2019, 21(12): 1654-1662. |
17 | HOMPLAND I, BRULAND Ø S, HØLMEBAKK T, et al. Prediction of long-term survival in patients with metastatic gastrointestinal stromal tumor: analysis of a large, single-institution cohort[J].Acta Oncol,2017,56(10):1317-1323. |
18 | SATO S, TSUJINAKA T, MASUZAWA T, et al. Role of metastasectomy for recurrent/metastatic gastrointestinal stromal tumors based on an analysis of the Kinki GIST registry[J]. Surg Today, 2017, 47(1): 58-64. |
19 | CAI Z, YIN Y, SHEN C, et al. Role of surgical resection for patients with recurrent or metastatic gastrointestinal stromal tumors: a systematic review and meta-analysis[J]. Int J Surg, 2018, 56: 108-114. |
20 | SCHRAGE Y, HARTGRINK H, SMITH M, et al. Surgical management of metastatic gastrointestinal stromal tumour[J]. Eur J Surg Oncol, 2018, 44(9): 1295-1300. |
21 | BAUER S, RUTKOWSKI P, HOHENBERGER P, et al. Long-term follow-up of patients with GIST undergoing metastasectomy in the era of imatinib: analysis of prognostic factors (EORTC-STBSG collaborative study)[J].Eur J Surg Oncol,2014,40(4):412-419. |
22 | SHANNON A B, SONG Y, FRAKER D L, et al. Do microscopic surgical margins matter for primary gastric gastrointestinal stromal tumor? [J]. Surgery, 2021, 169(2): 419-425. |
23 | HØLMEBAKK T, BJERKEHAGEN B, HOMPLAND I, et al. Relationship between R1 resection, tumour rupture and recurrence in resected gastrointestinal stromal tumour[J]. Br J Surg, 2019, 106(4): 419-426. |
24 | PANTUSO G, MACAIONE I, TAVERNA A, et al. Surgical treatment of primary gastrointestinal stromal tumors (GISTs):Management and prognostic role of R1 resections[J]. Am J Surg, 2020, 220(2): 359-364. |
25 | GRONCHI A, BONVALOT S, POVEDA VELASCO A, et al. Quality of surgery and outcome in localized gastrointestinal stromal tumors treated within an international intergroup randomized clinical trial of adjuvant imatinib[J].JAMA Surg,2020,155(6): e200397. |
26 | CORLESS C L, BARNETT C M, HEINRICH M C. Gastrointestinal stromal tumours: origin and molecular oncology[J]. Nat Rev Cancer, 2011, 11(12): 865-878. |
27 | ZONG L, CHEN P. Prognostic value of KIT/PDGFRA mutations in gastrointestinal stromal tumors: a meta-analysis[J]. World J Surg Oncol, 2014, 12: 71. |
28 | LASOTA J, DANSONKA-MIESZKOWSKA A, SOBIN L H, et al. A great majority of GISTs with PDGFRA mutations represent gastric tumors of low or no malignant potential[J]. Lab Invest, 2004, 84(7): 874-883. |
29 | ROSSI S, GASPAROTTO D, MICELI R, et al. KIT, PDGFRA, and BRAF mutational spectrum impacts on the natural history of imatinib-naive localized GIST: a population-based study[J]. Am J Surg Pathol, 2015, 39(7): 922-930. |
30 | SZUCS Z, THWAY K, FISHER C, et al. Molecular subtypes of gastrointestinal stromal tumors and their prognostic and therapeutic implications[J]. Future Oncol, 2017, 13(1): 93-107. |
31 | WOZNIAK A, RUTKOWSKI P, PISKORZ A, et al. Prognostic value of KIT/PDGFRA mutations in gastrointestinal stromal tumours (GIST):Polish Clinical GIST Registry experience[J].Ann Oncol, 2012,23(2): 353-360. |
32 | JOENSUU H, RUTKOWSKI P, NISHIDA T, et al. KIT and PDGFRA mutations and the risk of GI stromal tumor recurrence[J]. J Clin Oncol, 2015, 33(6): 634-642. |
33 | DEMETRI G D, WANG Y F, WEHRLE E, et al. Imatinib plasma levels are correlated with clinical benefit in patients with unresectable/metastatic gastrointestinal stromal tumors[J]. J Clin Oncol, 2009, 27(19): 3141-3147. |
34 | QIAN Y, SUN L N, LIU Y J, et al. Genetic polymorphisms and adverse events on unbound imatinib and its active metabolite concentration in patients with gastrointestinal stromal tumors[J]. Front Pharmacol, 2019, 10: 854. |
35 | VERBOOM M C, KLOTH J S L, SWEN J J, et al. Genetic polymorphisms in ABCG2 and CYP1A2 are associated with imatinib dose reduction in patients treated for gastrointestinal stromal tumors[J]. Pharmacogenomics J, 2019, 19(5): 473-479. |
36 | KOO D H, RYU M H, RYOO B Y, et al. Association of ABCG2 polymorphism with clinical efficacy of imatinib in patients with gastrointestinal stromal tumor[J]. Cancer Chemother Pharmacol, 2015,75(1): 173-182. |
37 | ANGELINI S, PANTALEO M A, RAVEGNINI G, et al. Polymorphisms in OCTN1 and OCTN2 transporters genes are associated with prolonged time to progression in unresectable gastrointestinal stromal tumours treated with imatinib therapy[J]. Pharmacol Res, 2013, 68(1): 1-6. |
38 | VERBOOM M C, KLOTH J S L, SWEN J J, et al. Genetic polymorphisms in angiogenesis-related genes are associated with worse progression-free survival of patients with advanced gastrointestinal stromal tumours treated with imatinib[J]. Eur J Cancer, 2017, 86: 226-232. |
39 | BRAHMI M, ALBERTI L, DUFRESNE A, et al. KIT exon 10 variant (c.1621 A>C) single nucleotide polymorphism as predictor of GIST patient outcome[J]. BMC Cancer, 2015, 15(1): 1-8. |
40 | ANGELINI S, RAVEGNINI G, NANNINI M, et al. Folate-related polymorphisms in gastrointestinal stromal tumours: susceptibility and correlation with tumour characteristics and clinical outcome[J]. Eur J Hum Genet, 2015, 23(6): 817-823. |
41 | GEDDERT H, BRAUN A, KAYSER C, et al. Epigenetic regulation of CD133 in gastrointestinal stromal tumors[J]. Am J Clin Pathol, 2017, 147(5): 515-524. |
42 | HALLER F, ZHANG J D, MOSKALEV E A, et al. Combined DNA methylation and gene expression profiling in gastrointestinal stromal tumors reveals hypomethylation of SPP1 as an independent prognostic factor[J]. Int J Cancer, 2015, 136(5): 1013-1023. |
43 | NIINUMA T, KAI M, KITAJIMA H, et al. Downregulation of miR-186 is associated with metastatic recurrence of gastrointestinal stromal tumors[J]. Oncol Lett, 2017, 14(5): 5703-5710. |
44 | WANG Y, LI J, KUANG D, et al. miR-148b-3p functions as a tumor suppressor in GISTs by directly targeting KIT[J].Cell Commun Signal,2018,16(1): 16. |
45 | LONG Z W, WU J H, CAI-HONG, et al. MiR-374b promotes proliferation and inhibits apoptosis of human GIST cells by inhibiting PTEN through activation of the PI3K/Akt pathway[J].Mol Cells,2018,41(6): 532-544. |
46 | LIU X, QIU H, ZHANG P, et al. Ki-67 labeling index may be a promising indicator to identify “very high-risk” gastrointestinal stromal tumor: a multicenter retrospective study of 1022 patients[J]. Hum Pathol, 2018, 74: 17-24. |
47 | ZHAO W Y, XU J, WANG M, et al. Prognostic value of Ki67 index in gastrointestinal stromal tumors[J]. Int J Clin Exp Pathol, 2014, 7(5): 2298-2304. |
48 | MARTINHO O, GOUVEIA A, SILVA P, et al. Loss of RKIP expression is associated with poor survival in GISTs[J]. Virchows Arch, 2009, 455(3): 277-284. |
49 | WANG Y, CHEN J J, WANG X F, et al. Clinical and prognostic significance of Raf kinase inhibitory protein expression in gastrointestinal stromal tumors[J]. World J Gastroenterol, 2018, 24(23): 2508-2517. |
50 | WANG J L, WU J H, HONG C, et al. Involvement of Bmi-1 gene in the development of gastrointestinal stromal tumor by regulating p16Ink4A/p14ARF gene expressions: an in vivo and in vitro study[J]. Pathol Res Pract, 2017, 213(12): 1542-1551. |
51 | ZHU K, LI K, YUAN D W, et al. Clinicopathological and prognostic significance of expression of B-cell-specific moloney murine leukemia virus insertion site 1 (BMI-1) gene and protein in gastrointestinal stromal tumors[J]. Med Sci Monit, 2018, 24: 6414-6421. |
52 | RIZZO F M, PALMIROTTA R, MARZULLO A,et al.Parallelism of DOG1 expression with recurrence risk in gastrointestinal stromal tumors bearing KIT or PDGFRA mutations[J]. BMC Cancer, 2016, 16: 87. |
53 | LI Q, ZHI X, ZHOU J, et al. Circulating tumor cells as a prognostic and predictive marker in gastrointestinal stromal tumors: a prospective study[J]. Oncotarget, 2016, 7(24): 36645-36654. |
54 | JUNG S H, SUH K S, KANG D Y, et al. Expression of DOG1, PDGFRA, and p16 in gastrointestinal stromal tumors[J]. Gut Liver, 2011, 5(2): 171-180. |
[1] | Liantao HU,Wenjun DENG,Shizhen LU,Luo SUN,Xuebing LI,Chuhao LI,Xinran WANG,chunbing ZHANG,Yue LI,Weiqun WANG. Bioinformatics analysis on CC chemokine ligand 20 expression in hepatocellular carcinoma tissue and its effect on prognostic assessment of liver hepatocellular carcinoma [J]. Journal of Jilin University(Medicine Edition), 2022, 48(4): 1010-1017. |
[2] | Yan SUN,Xinhua DONG,Dongying LI,Qingfen ZHENG,Huiyu YANG,Bingrong LIU. Investigation and analysis on cognition of first-degree relatives of patients with colorectal cancer on colorectal cancer screening [J]. Journal of Jilin University(Medicine Edition), 2022, 48(4): 1065-1070. |
[3] | . Research progress in regulatory effect of intestinal microecology on intestinal immune homeostasis and epigenetic modification and its relationship with occurrence and development of colorectal cancer [J]. Journal of Jilin University(Medicine Edition), 2022, 48(4): 1071-1078. |
[4] | Yandi MA,Xiangyun LU,Shangfeng HE,Xueyan YU,Yunhua HU,Haixia GAO,Yunzhao CHEN,Jie YU,Wenjie WANG,Feng LI,Xiaobin CUI. Expression of m6A methylation binding protein YTHDF2 in esophageal carcinoma tissue and its effect on proliferation and migration of esophageal carcinoma cells [J]. Journal of Jilin University(Medicine Edition), 2022, 48(4): 962-970. |
[5] | Yingjie NIU,Yong ZHA,Sijia LI,Qing WANG,Shicong TANG,Hongyang LI. Analysis on prognosis related factors of patients with cholangiocarcinoma after radical resection and establishment of survival prediction model [J]. Journal of Jilin University(Medicine Edition), 2022, 48(4): 979-987. |
[6] | Qiuting CAO,Jingchun HAN,Xiaofei ZHANG. Effect of silencing helicase BLM gene on chemotherapy sensitivity of irinotecan in colorectal cancer cells and its mechanism [J]. Journal of Jilin University(Medicine Edition), 2022, 48(3): 657-667. |
[7] | Qian LIU,Guoping QI,Huayi YU,Yuyang DAI,Wenbin LU,Jianhua JIN. Bioinformatics analysis on screening of colon cancer core genes and independent prognostic factors [J]. Journal of Jilin University(Medicine Edition), 2022, 48(3): 755-765. |
[8] | Suxian CHEN,Zehui GU,Yangfei MA,Qi TAN,Qi LI,Yadi WANG. Promotion effect of rutin on apoptosis of human colon cancer SW480 cells and its mechanism [J]. Journal of Jilin University(Medicine Edition), 2022, 48(2): 356-363. |
[9] | Chengsheng LI,Qihan BAO,Xiaoyan HAO,Qingzhong PAN,Suzhen WANG,Fuyan SHI. Establishment of prediction model for postoperative pancreatic cancer based on random forest algorithm [J]. Journal of Jilin University(Medicine Edition), 2022, 48(2): 426-435. |
[10] | Chaofeng ZHOU,Shifan ZHOU,Qing TIAN,Sai WANG,Honglin LI,Chunzheng MA. Effect of lncRNA-NORAD overexpression on biological behaviors of esophageal cancer Eca-109 cells and its mechanism [J]. Journal of Jilin University(Medicine Edition), 2022, 48(1): 33-43. |
[11] | Lili QIN,Xiaobo MA,Tianye ZHAO,Xuerong TAO,Min ZHENG,Xueying WANG,Jiaxin YI,Yanhua WU,Jing JIANG. Effects of MMP-9 and TIMP-1 expressions on prognostic evaluation of gastric cancer patients after radical gastrectomy [J]. Journal of Jilin University(Medicine Edition), 2022, 48(1): 163-171. |
[12] | Guangsong XU,Haibing JIANG,Jing PAN,Guoqing LI. Inhibitory effects of betulinic acid on migration and invasion of gastric cancer MGC-803 cells and their mechanisms [J]. Journal of Jilin University(Medicine Edition), 2022, 48(1): 122-128. |
[13] | Runhong MU,Yijiu AI,Yupeng LI,Rui LIN,Siping YE,Fang MA,Xiao GUO. Expression of recombinant human IL-17A in gastric cancer tissue and its effects on proliferation, invasion, migration and apoptosis of gastric cancer BGC-823 cells [J]. Journal of Jilin University(Medicine Edition), 2021, 47(6): 1510-1517. |
[14] | Lili HUANG,Yuxuan LIU,Kaiyi FANG,Yeteng MU,Nannan HU,Chong GUO,Fuxu YANF,Xingang GUAN. Preparation of oxaliplatin-loaded cell membrane nanodrugs and its killing effect on colon cancer cells of mice [J]. Journal of Jilin University(Medicine Edition), 2021, 47(6): 1422-1428. |
[15] | Yajie CAO,Xiaohong BAO,Shuzhen LI,Haiying GENG,Zengxiaorui CAI,Chunmei DAI,Ning LI. Effects of insulin-like growth factor 1 receptor inhibitor NVP-AEW541 on proliferation, migration and invasion of ESCC cells [J]. Journal of Jilin University(Medicine Edition), 2021, 47(5): 1131-1138. |